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To compare the antitumor eﬃcacy and safety of transcatheter arterial chemoembolization (TACE) by epirubicin suspension (epi-
rubicin suspension: epirubicin-iodized oil mixture without solution) to that by epirubicin emulsion (epirubicin emulsion: epiru-
bicin-iodizedoilmixturewithsolution),theeﬃcacyoftreatmentbyadministrationofeitheranepirubicinsuspensionoremulsion
was examined in an animal model. Changes in plasma epirubicin concentration were compared over 24h immediately after treat-
ment, and enhanced ultrasonographic and histopathological analysis subsequently conducted 7 days after treatment to determine
thegrowthratioandproportionofviabletumorcells.Thegrowthratioandproportionofviabletumorcellswerefoundtobesigni-
ﬁcantly lower in the suspension group than in the emulsion group while the plasma epirubicin concentration was found to be sig-
niﬁcantly higher in the suspension group than in the emulsion group. These results indicate that administration of an epirubicin
suspension is a superior form of TACE compared to that of administration of an epirubicin emulsion.
1.Introduction
The incidence of hepatocellular carcinoma (HCC), the
fourth most common cause of cancer-related death world-
wide, is currently increasing [1]. Fortunately, in developed
countries, HCC is diagnosed in 30 to 40% of all patients at
the early stages, when it is amenable to treatment, such as
surgical therapy and percutaneous treatment [2]. However,
nosystemictherapyhasyetbeendevelopedthatimprovesthe
survival of patients with advanced HCC [3, 4]. One eﬀective
treatment may be administration of sorafenib (Nexavar;
Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals,
Leverkusen, Germany), a molecular target-based drug that
a recent study found could improve prognosis modestly [5].
Whereas 80% of the blood to healthy liver tissue is sup-
plied by the portal vein, 99% of the blood to hepatic tumors
is delivered by the hepatic artery.
Based on this observation, transcatheter arterial chemo-
embolization (TACE), a more recent interventional treat-
ment for HCC that is appropriate for patients for whom
surgical or percutaneous ablative treatment is contraindi-
cated,currentlyplaysamajorroleintreatingadvancedHCC.
Support for its use was provided by the results of 2 random-
ized controlled trials and a meta-analysis, which indicated its
survival beneﬁts [6–8]. The protocol for TACE is injection
of both iodized oil and anticancer agents into the hepatic
artery, followed by administration of embolic agents [9, 10].
Several anticancer agents are used in TACE, including mito-
mycin, doxorubicin, and cisplatin. Among these agents, epi-
rubicin, the anticancer agent examined in this study, is one
of the most commonly used in treating advanced HCC
worldwide [11]. Although doxorubicin-eluting beads (DC
Beads; Biocompatibles, UK Ltd.) have recently been used
as part of a novel drug-delivery embolization system, their
superiority to other agents has not yet been proven [12], nor
has their use been approved in several countries, including
Japan.
As maximizing antitumor eﬃcacy requires transfer of an
adequate drug concentration to the target cancer cells for
retention in the lesion for a suﬃcient period [13], drug-
iodized oil mixtures that provide sustained release are
preferred agents in TACE. Among the types of mixtures that
can be used in TACE, water-in-oil (water droplets dispersed2 The Scientiﬁc World Journal
Figure 1:TACEprocedure.Thetherapeuticagentwasadministered
via a 2.3-Fr microcatheter inserted into the middle hepatic artery
(arrows), which can be seen feeding the tumor (arrowheads).
inoil)emulsionshavebeenfoundtoexertastrongerembolic
eﬀect in HCC treatment compared to oil-in-water (oil drop-
lets dispersed in water) emulsions [14], as well as a greater
capacity for sustained release [14, 15]. Although several
studies have conﬁrmed that suspensions are more eﬀective
than emulsions in providing sustained drug release [15–17],
no study to date has compared the antitumor eﬃcacy of sus-
pensions and emulsions of an anticancer drug in experimen-
tally induced liver tumors.
To ﬁll this research gap, this study compared the antitu-
mor eﬃcacy and safety of TACE performed by administra-
tion of an epirubicin-iodized oil suspension to that of TACE
performed by administration of an epirubicin-iodized oil
emulsion in the treatment of experimentally induced liver
tumors in an animal model.
2.MaterialsandMethods
2.1. Animals. All experiments were performed using 10
female Japanese white rabbits (2.9–3.5kg; mean, 3.06kg;
SLC, Tokyo, Japan) according to a protocol that had been
approved by the Animal Experiment Ethics Committee of
the university at which the study was conducted. Prior to
study initiation, the VX2 carcinoma strain, a known model
of hypervascular tumor, had been maintained by successive
transplantation into the hindlimb of a carrier rabbit.
Experimentation began 3 weeks after 0.1mL of minced
VX2 carcinoma had been implanted into the subcapsular
parenchyma of the left medial liver lobe of the 10 rabbits
through a midline abdominal incision. In all experiments,
the rabbits were anesthetized by intravenous injection of
thiopentalsodium(40mg/(kg·h)−1;Ravonal,Tanabe-Mitsu-
bishi, Osaka, Japan).
2.2. Experimental Groups. After all 10 rabbits had been inoc-
ulated with VX2 carcinoma cells, 5 were randomly assigned
to the emulsion group (weight range 2.9–3.2kg; mean,
3.01kg) and 5 to the suspension group (weight range 2.9–
3.5kg;mean,3.08kg).Theemulsiongroupwasadministered
0.5mg/kg of epirubicin (Lipiodol Ultra-Fluide; Laboratoire
Guerbet, Aulnay-Sous-Bois, France) in 0.1mL/kg of iodized
oilwith0.1mL/kgsalinesolutionwhilethesuspensiongroup
was administered 0.5mg/kg of epirubicin in 0.1mL/kg of
iodized oil without saline solution. To prepare the emulsion,
10mg epirubicin was dissolved in 2mL of saline solution, of
which 2mL (5mg/mL) had been mixed with 2mL of iodized
oil by use of a pumping method consisting of 20 pushes and
pulls through a stopcock between 2 disposable syringes (1
push and pull per 2s) immediately before infusion [18]. To
preparethesuspension,10mgofepirubicinwasmixeddirec-
tly with 2mL of iodized oil by manual stirring, followed by
use of the same pumping method used to prepare the emul-
sion immediately before infusion.
2.3. TACE Procedure. Three weeks after implantation of the
VX2 carcinoma, TACE was performed by experienced inter-
ventional radiologists (T. Ueda, S. Murata, T. Mine, and S.
Onozawa) under ﬂuoroscopic guidance. After general anes-
thesia had been induced, the right femoral artery was ex-
posed by an incision for insertion of a 4-Fr sheath (Medikit
Co.,Tokyo,Japan).Celiacangiographywasperformedwitha
4-Fr Cobra-type catheter (Medikit Co.) to reveal the hepatic
arterial anatomy and identify the artery feeding the tumor.
The middle hepatic artery, which exclusively supplied blood
to the tumor in all the rabbits, was selectively catheterized
using a 2.3-Fr microcatheter (Transit; Cordis, Miami, FL).
After the catheter had been advanced to a suitable position in
the artery, the emulsion or suspension was carefully injected
to avoid eﬄuxion of the embolic material (Figure 1). The
catheter was then removed, and the femoral artery ligated.
2.4. Tumor Size Analysis. Tumor size was measured by per-
forming abdominal ultrasonography (Acuson Sequoia 512;
Siemens Medical Systems, Erlangen, Germany) with an elec-
tronic linear probe (15L8W) immediately before and 7 days
after TACE with the animals in the supine position. En-
hanced ultrasonography was enabled by a single injection of
0.015mL/kg of Sonazoid (Daiichi-Sankyo, Tokyo, Japan) in
the auricular vein. Using the images obtained by Kupﬀer-
phase scanning (20 frames/s; 10–13MHz; cadence contrast
pulse sequence mode) at 10-min intervals, tumor location
and size in the sagittal section were measured 3 times by ex-
perienced radiologists (T.U. and M.T.) and the average size
wascalculatedbyconsensus(Figures2(a)and2(b)).Thearea
(A) of the tumor, which was considered to assume an elliptic
shape, was calculated using the formula A = L ×S/4 ×3.14,
where L and S are the longest and shortest diameters of the
tumor, respectively. The average of 3 consecutive measure-
ments of the diameter was utilized for the calculation. The
growth ratio was calculated by comparing the tumor area
obtained before (A0)a n d7d a y sa f t e r( A7) treatment using
the formula ((A7/A0) −1) ×100.
At 7 days after TACE, the rabbits were sacriﬁced by
overdose of thiopental sodium for histological investigation.The Scientiﬁc World Journal 3
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Figure 2: Sonazoid-enhanced ultrasonographic and histopathological examination. (a) Immediately after Sonazoid administration, the
tumor shows a strong contrast eﬀect, depending on the vascular distribution, particularly in the marginal area (arrowheads). (b) While
the tumor lacks a contrast eﬀect 10min after administration of Sonazoid (the Kupﬀer phase), the edge can be clearly visualized (arrows).
(c)Cellularcolonieswithadequatelystainednucleiandcytoplasmcanbeobservedintheviable(c)butnotthenecroticportion(d).Adeposit
of iodized oil (I) remains in the destroyed vascular structure (e). (c–e): hematoxylin-eosin staining, 20x original magniﬁcation.
After extirpation, the tumors were sliced sagittally and mea-
sured macroscopically. The macroscopic measurements were
evaluated statistically and compared to the ultrasonographic
measurements to determine the accuracy of the latter.
2.5. Histopathological Examination. After extirpation, the
rabbit livers were ﬁxed in a 20% formaldehyde solution. The
tumor-containing portion was sliced at 5mm intervals in the
sagittal plane to correspond to the plane of the ultrasound
imaging. The resulting 4µm sections were embedded in par-
aﬃn and stained with hematoxylin and eosin for histological
examination, with the largest and second largest tumor
sections also utilized for pathological investigation. Cellular
colonies for which adequately stained nuclei and cytoplasm
that could be observed under microscopic examination were
classiﬁed as viable, while colonies for which inadequate
nuclear staining or lacking nuclei or cytoplasm that could
be observed were classiﬁed as necrotic (Figures 2(c)–2(e)).
Experienced pathologists (M. Onda and Z. Naito) evaluated
the histological changes and extent of necrosis in the tumors.4 The Scientiﬁc World Journal
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Figure3:Correlationbetweenultrasonographicanddirect(macro-
scopic) measurements of tumor size. Pearson’s correlation coeﬃ-
cient (R2) between the ultrasonographic and the direct measure-
ments was found to be 0.84 (n = 10, P<0.001).
Antitumor eﬀects were quantiﬁed by estimating the viable
proportion of the entire tumor, with the overall proportion
of the viable tumor calculated on the basis of the mean per-
centage in each slice.
2.6. Pharmacokinetics and Toxicity. Blood samples were col-
lectedfromtheauricularveinat0,0.5,1,3,6,and24himme-
diately after administration. The samples were centrifuged
and the plasma was utilized for measuring the epirubicin
concentration, an indicator of the extent of sustained action.
The extent of hepatic and hematological toxicity experienced
by the 2 groups was evaluated by drawing peripheral blood
from the auricular vein before and at 1, 3, 5, and 7 days
after TACE for measurement of plasma aspartate amino-
transferase (AST), alanine aminotransferase (ALT), and total
bilirubin (T-Bil) levels.
2.7. Statistical Analysis. The correlation between ultrasono-
graphicanddirectmeasurementsoftumorsizewasevaluated
by calculating Pearson’s correlation. The antitumor eﬃcacy
(i.e., impact on tumor growth ratio and viable proportion)
of the 2 forms of treatment was compared by performing
Mann-Whitney U testing. Plasma epirubicin concentration
and biochemical levels were compared by performing un-
paired t testing. SPSS version 14 (SPSS Japan, Tokyo, Japan)
was used to perform all statistical analyses and all P values
less than 0.05 were considered statistically signiﬁcant. All
data are presented as the mean ± standard deviation.
3. Results
TACEwasperformedsuccessfullyforallrabbits,asevidenced
by the 0% mortality rate over the 7-day treatment period.
Blood samples were obtained over the study period and
Table 1: Plasma epirubicin concentration.
Time Suspension form Emulsion form P
(h) (ng/mL) (ng/mL)
0 205.73 ± 120.14 173.20 ± 110.58 0.69
0.5 3.53 ± 1.25 2.18 ± 1.90 0.26
13 . 5 5 ± 1.05 1.26 ± 1.22 0.02
32 . 3 3 ± 0.85 1.38 ± 1.33 0.26
61 . 0 6 ± 1.93 1.32 ± 1.42 0.81
24 0.98 ± 1.28 0.62 ± 0.85 0.63
Values are expressed as mean ± SD (n = 5 each).
microscopic sections immediately after the treatment period
from all rabbits.
3.1. Change in Tumor Size. The diﬀerence between the mean
tumor sizes at baseline (A0 ± SD) of the emulsion and sus-
pensions groups, which were calculated as 2.35 ± 0.75cm2
and 3.04 ± 0.44cm2, respectively, was not found to be sta-
tistically signiﬁcant (P>0.05, Mann-Whitney U test). Sta-
tistical comparison of the results of ultrasonographic exam-
ination 7 days after treatment (A7), which revealed that the
tumor area ranged from 2.03 to 4.14cm2 (2.83 ± 0.7cm2),
and macroscopic analysis, which revealed that the tumor size
ranged from 2.14 to 4.00cm2 (2.85 ± 0.7cm2), indicated
a signiﬁcant correlation between the ultrasonographic and
direct measurements of tumor size (R2 = 0.84, P<0.001;
Figure 3). During the experimental period, the tumors in the
suspension group were observed to exhibit minimal growth
or slight shrinkage (Figure 4(a)) and a growth ratio ranging
from −18.4 to 9.4% (−7.3 ± 11.3%). In contrast, the tumors
in the emulsion group were found to display a signiﬁcantly
smaller growth ratio (P = 0.016, Mann-Whitney U test) and
an increase in volume ranging from 6.6% to 40.4% (21.4 ±
12.6%).
3.2. Viable Proportion. On microscopic examination, both
viable and necrotic tumor cells were observed in all spec-
imens. The proportion of viable tumor cells depended on
vessel damage, with strong vessel damage leading to a rela-
tivelysmallerviableproportion.Statisticalcomparisonofthe
viable proportion of the tumors in the suspension group,
which ranged from 16.6 to 41.1% (28.0 ± 10.4%), and the
emulsion group, which ranged from 31.6 to 58.7% (49.6 ±
10.5%), indicated that the proportion of viable tumor cells
was signiﬁcantly smaller in the suspension group than in
the emulsion group (P = 0.028, Mann-Whitney U test;
Figure 4(b)).
3.3. Pharmacokinetics and Toxicity. Table 1 shows the sequ-
ential changes observed in plasma epirubicin concentration.
At 1h after administration, the concentration of the suspen-
sion group was found to be signiﬁcantly higher than that of
the emulsion group (P = 0.02, unpaired t test). However,
the diﬀerence in concentration between the 2 groups did not
reach a level of statistical signiﬁcance at 0.5, 3, 6, and 24hThe Scientiﬁc World Journal 5
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Figure 4: Growth ratio and viable proportion. (a) Graph showing the macroscopically determined growth ratio of liver tumors 7 days after
TACE. The tumors in the suspension group showed minimal growth or slight shrinkage over the experimental period, while those in the
emulsion group exhibited a mild increase in volume. The growth ratio of the tumors in the suspension group was found to be signiﬁcantly
smaller than that in the emulsion group (P = 0.016, Mann-Whitney U test). (b) Graph showing the viable proportion of liver tumors at
7 days after TACE. The percentage of residual viable tumor cells ranged from 16.6% to 41.1% in the suspension group and from 31.6% to
58.7% in the emulsion group. The proportion of viable tumor cells was found to be signiﬁcantly smaller in the suspension group than in the
emulsion group (P = 0.028, Mann-Whitney U test).
after administration. As can be observed in Figure 5,w h i c h
shows the plasma AST and ALT levels before and after TACE,
ASTandALTlevelsweretransientlybutsigniﬁcantlyelevated
at 24h after TACE, but decreased to approximately normal
levels at 7 days after TACE. No signiﬁcant diﬀerences were
found in the AST or ALT levels between the 2 groups over
the study period nor were any signiﬁcant changes in plasma
T-Bil levels observed in either group.
4. Discussion
Asanembolicmaterial,iodizedoilhasseveralcharacteristics,
including a high level of viscosity, that allows it to destroy
peribiliary plexus or peripheral arterioles [19]. Moreover,
as iodized oil is distributed according to the vascularity of
organs or tumors, it can be selectively deposited for an
extended period in areas that have become necrotic due to
its injection [20].
Histopathologically, simultaneous administration of
anticancer drugs and iodized oil emulsions has been found
to provide better therapeutic eﬀects than administration of
iodized oil alone [21, 22]. Speciﬁcally, the results of ran-
domizedtrialsoftranscatheterarterial-infusiontherapywith
epirubicin with and without iodized oil, which found that
administration of an epirubicin-iodized oil emulsion was
more eﬀective than that of epirubicin alone (response rate,
42% and 12%, resp.) [23], suggest that administration of
anticancer-drug-iodized-oil emulsions exerts more potent
antitumor eﬀects than administration of iodized oil or drugs
alone.
In the treatment of portal vein ischemia, which results in
injury to the portal vein endothelium and thrombus forma-
tion, anticancer drugs contained in iodized oil have been
found to exert antitumor eﬀects. Speciﬁcally, iodized oil has
been observed to traverse the sinusoids from the portal
venules into the hepatic vein, where oil droplets are immedi-
ately washed into the systemic circulation. The time required
for clearance of iodized oil from the liver and recovery of
the microcirculation depends largely on the patency of the
hepatic artery. The iodized oil activates Kupﬀer cells, which
capture and phagocytose the oil in hepatic sinusoids and
likely exert a synergistic tumoricidal eﬀect toward hepatic
tumors [24]. As such, TACE-induced anticancer eﬀects and
damage to tumor and/or peritumoral vessels are closely re-
lated [25].
In this study, evaluation of the combined antitumor ef-
fects of epirubicin and iodized oil in a group administered
the treatment in suspension form and a group administered
the treatment in an emulsion group revealed a signiﬁcant
correlation between the ultrasonographic and macroscopic
measurements of the tumors (R2 = 0.84, P<0.001), indicat-
ing that tumor size can be accurately measured by Sonazoid-
enhanced ultrasonography. The growth ratio in the suspen-
sion group was found to be smaller than that in the emulsion
group, indicating that providing epirubicin in suspension
form yields a much stronger antitumor eﬀect compared to6 The Scientiﬁc World Journal
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Figure 5:Levelsoftoxicity.ASTandALTlevelsincreasedforseveral
days after TACE, and did not recover to baseline levels during the
experimental period. Although the levels of the suspension group
increased to a slightly greater extent compared to those of the emul-
siongroup,thediﬀerencesbetweenthelevelsofthe2groupsdidnot
reach a level of statistical signiﬁcance. No signiﬁcant changes were
observed in the T-Bil level of either group.
administering it in emulsion form. This indication was sup-
ported by the results of histopathological analysis, which
revealed that administration in suspension form led to more
severe damage to the tumor and/or peritumoral vessels, and
thus a much better antitumor eﬀect.
Microscopic analysis of the extent of necrosis of tumor
cellscausedbyischemiaduetovesseldamage,withalowpro-
portionofviabletumorcellsindicatinggreatervesseldamage
[25], revealed that the area of viable tumor cells depends on
the extent of vessel damage. Speciﬁcally, greater vessel dam-
age, which causes intimal proliferation, thrombi, and deg-
enerativechanges,leadstoarelativelydecreasedviabletumor
area.
The administration of sustained-release anticancer
agents can reduce drug leakage into the peripheral blood,
allowing for maintenance of a high local drug concentration
in tumors and drug distribution to plasma at a relatively
slower rate. Research has demonstrated that the release rate
of anticancer agents can be controlled by modifying the form
in which they are administered, with the suspension form
being found superior to the emulsion form in maintaining
sustained agent release [15–17]. In this study, the suspension
form (without water) was found to remain within the tumor
and plasma for a longer period compared to the emulsion
form (with water). As the distribution half-life of epirubicin
is extremely brief (approximately 4.67min) [26], the highest
epirubicin concentration in both groups was observed im-
mediately after injection.
While the epirubicin concentration in both groups was
observed to decrease rapidly 0.5h after administration, the
concentration in the suspension group was found to be
signiﬁcantly higher than that in the emulsion group at 1h
after administration. This ﬁnding indicates that epirubicin
remained within the tumors for a longer period and was dis-
tributed more slowly to the plasma in the suspension group,
suggesting that the suspension form provides a greater ex-
tent of sustained release compared to the emulsion form.
However, this conclusion has a signiﬁcant caveat: as a signi-
ﬁcant diﬀerence in plasma concentration was observed at
a single isolated point—at 1h after administration—this
observation might be able to be attributed to the very short
half-life of epirubicin. Therefore, the next step in this line
of research is investigation of the time-concentration curve
of epirubicin within tumors for more speciﬁc analysis of the
antitumor eﬀects of the suspension.
In accordance with previous clinical research, which
found that liver enzymes commonly increase transiently fol-
lowingTACE,peakingat24–36hbeforereturningtobaseline
levels at 5–7 days [27–30], the AST and ALT levels of all the
rabbits in this study were found to increase transiently before
returning to baseline levels over the 7-day experimental
period. Moreover, no signiﬁcant diﬀerences in liver enzyme
levels were observed between the groups, demonstrating the
safety of both the suspension and emulsion forms. However,
the increase in liver enzymes was found to be slightly great-
er in the suspension group, which might have been related to
greater damage to the tumors and/or peritumoral vessels in
this group. These results suggest that intra-arterial adminis-
tration of epirubicin in suspension form allows for its accu-
mulation in a liver tumor, and may thus be a useful method
for reducing systemic toxicity.
The fact that very little research [18]h a sb e e nc o n d u c t e d
into the use of an epirubicin-iodized oil suspension for
treatinglivertumorsmaybeattributedtothewatersolubility
of epirubicin, a characteristic that poses diﬃculty in creating
a suspension. Indeed, diﬃculty in mixing epirubicin with
iodized oil was a major limitation of this study, requiring
that the suspension be prepared using manual stirring and
a pumping method. Therefore, eﬃcient preparation of epi-
rubicin-iodized oil suspensions remains a major concern.
In conclusion, this study found that administration of an
epirubicin-iodized oil suspension yields superior anticancer
eﬃcacycomparedtoadministrationofanepirubicin-iodized
oil emulsion while posing a relatively low risk of toxicity in
the treatment of hepatic tumors. As the next stage in the re-
search into the best form of HCC treatment, a randomized
controlled trial will be conducted to compare the antitumor
eﬀects of TACE with an epirubicin-iodized oil suspension to
that of TACE with an epirubicin-iodized oil emulsion.
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